Antibioticoterapia para infecções por bactérias gram-positivas no paciente grave

Campos, Stella Caldas; Tanure, Isabella de Queiroz; Chebabo, Alberto; Nacul, Flavio Eduardo.
J. bras. med ; 92(4): 21-30, abr. 2007. tab
Artículo en Portugués | LILACS | ID: lil-478504

Documentos relacionados

  1. Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical Information.
  2. Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
  3. Accuracy of Therapeutic Drug Monitoring of Teicoplanin at the Onset of Febrile Neutropenia.
  4. Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.
  5. Non-<i>faecium</i> non-<i>faecalis</i> enterococci: a review of clinical manifestations, virulence factors, and antimicrobial resistance.
  6. Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?
  7. The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.
  8. Ability of Bicarbonate Supplementation To Sensitize Selected Methicillin-Resistant <i>Staphylococcus aureus</i> Strains to ß-Lactam Antibiotics in an <i>Ex Vivo</i> Simulated Endocardial Vegetation Model.
  9. Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round.
  10. [Dalbavancin: pharmacokinetic and pharmacodynamic parameters].